Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
5370277
Reference Type
Journal Article
Title
Skin testing for prognosis or therapy formulation in cancer patients: caveat emptor
Author(s)
Mandel, MA
Year
1976
Is Peer Reviewed?
1
Journal
Plastic and Reconstructive Surgery
ISSN:
0032-1052
EISSN:
1529-4242
Volume
57
Issue
5
Page Numbers
621-626
Language
English
PMID
1273144
DOI
10.1097/00006534-197605000-00010
Abstract
Delayed cutaneous hypersensitivity to DNCB was assessed in 56 patients who had epidermoid intraoral carcinoma, prior to therapy. They were followed for 44 months, and their skin reactivity correlated well with both a small tumor size and a favorable clinical prognosis. In a significant number of cases, however, lack of reactivity did not indicate a fatal outcome. Therefore, we recommend caution in the use of any skin test data in formulating therapy. When cured cancer patients were skin-tested, there was no correlation between the state of the disease and their skin reactivity.
Tags
PPRTV
•
1,3-Dinitrobenzene 2021
Literature Search June 2021
Scopus (July 2021)
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity